ADVFN - Advanced Financial Network.
HOME» NASDAQ » T » TEVA Stock Price » TEVA Stock News

Teva Pharmaceutical Share News

 Teva Pharmaceutical Industries Limited (mm) Stock Price
TEVA Stock Price
 Teva Pharmaceutical Industries Limited (mm) Stock Chart
TEVA Stock Chart
 Teva Pharmaceutical Industries Limited (mm) Stock News
TEVA Stock News
 Teva Pharmaceutical Industries Limited (mm) Company Information
TEVA Company Information
 Teva Pharmaceutical Industries Limited (mm) Stock Trades
TEVA Stock Trades

Teva Pharma Reduces 2012 Guidance On Lower Generics View

DOW JONES NEWSWIRES Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) lowered its guidance for 2012 on reduced expectations for generic drug sales in the U.S. and Europe, as well as softer sales of some branded offerings. The world's biggest manufacturer of generic drugs now expects per-share earnings of $5.30 to $5.40 on net sales of $20 billion to $21 billion. The Israel company in December had projected per-share earnings of $5.48 to $5.68 on revenue of $22 billion. The company reduced its outlook for generic drugs to $10.7 billion from its prior view of $11.8 billion. U.S. generic sales are pegged at $4.6 billion, down from $5 billion. Europe sales are seen at $3.4 billion, compared with a prior estimate of $4 billion. The reduced forecast for branded drugs includes its outlook for leukemia drug Treanda and its women's health products. Teva recently reported its first-quarter profit jumped 41%, as strong sales of branded and generic medicines in the U.S. and emerging markets offset a weak performance in Europe. The company's American depositary shares were up 1.4% at $39.10 in premarket trading after trading around $39.50 earlier. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Teva Pharmaceutical (TEVA)
DateTimeHeadline
03/30/201508:14:08Teva to Acquire Auspex in $3.2 Billion Deal
03/23/201509:59:36Teva Migraine Therapy Shows Positive Results in Phase IIb Study
03/02/201509:50:38Correction to Story About Teva Selling Pennsylvania Facility
03/02/201509:18:27Teva Sells Pennsylvania Facility to G&W Laboratories
02/17/201508:33:57Teva to Distribute Eagle Pharmaceutical's Cancer Drug in U.S.
01/26/201508:10:04FDA Rejects Antares' Application for Generic Migraine Drug
08/19/201401:55:00Gamida Cell Announces Investment and Option Agreement with Major...

Teva Pharmaceutical and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad